The Efficacy of Jinlida Granules on Type 2 Diabetes Mellitus was Discussed Based on the Theory of “Treating from Spleen”

Objective: To explore the clinical efficacy of the spleen-strengthening and body fluid-moving formula, Jinlida Granules, in combination with Metformin for treating type 2 diabetes based on the theory of ‘treating from the spleen.’ Methods: A case-control study was conducted, involving 62 patients with type 2 diabetes admitted between August 2022 and December 2024. These patients were randomly divided into a control group (31 patients treated with Metformin) and an observation group (31 patients treated with Jinlida Granules), both for a 12-week course of treatment. The study compared changes in blood glucose levels (FPG, 2hPG, HbA1c), lipid levels (TC, TG, LDL, HDL), and pancreatic function indicators (HOMA-B, HOMA-IR) before and after treatment in both groups, and assessed the overall clinical effectiveness. Results: The overall effectiveness rate of the observation group was 90.3%, significantly higher than the 74.2% in the control group (P < 0.05). After treatment, the FPG in the observation group decreased by 2.1 ± 0.8% mmol/L, and HbA1c decreased by 1.5 ± 0.6%. Additionally, the 2hPG in the observation group was significantly better than that in the control group, with a 18.3 ± 5.2% increase in HOMA-B and a 1.5 ± 0.6% decrease in HOMA-IR, all of which were better than those in the control group (P < 0.05). Conclusion: Jinlida Granules combined with Metformin can significantly improve the glucose and lipid metabolism and pancreatic cell function in patients with type 2 diabetes